ATE245703T1 - Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren - Google Patents

Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren

Info

Publication number
ATE245703T1
ATE245703T1 AT93920989T AT93920989T ATE245703T1 AT E245703 T1 ATE245703 T1 AT E245703T1 AT 93920989 T AT93920989 T AT 93920989T AT 93920989 T AT93920989 T AT 93920989T AT E245703 T1 ATE245703 T1 AT E245703T1
Authority
AT
Austria
Prior art keywords
gene
particles
hapten
retroviral
virus
Prior art date
Application number
AT93920989T
Other languages
English (en)
Inventor
Stephen James Russell
Robert Edward Hawkins
Gregory Paul Winter
Original Assignee
Biofocus Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220010A external-priority patent/GB9220010D0/en
Priority claimed from GB939304962A external-priority patent/GB9304962D0/en
Application filed by Biofocus Discovery Ltd filed Critical Biofocus Discovery Ltd
Application granted granted Critical
Publication of ATE245703T1 publication Critical patent/ATE245703T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT93920989T 1992-09-22 1993-09-22 Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren ATE245703T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929220010A GB9220010D0 (en) 1992-09-22 1992-09-22 Recombinant virus
GB939304962A GB9304962D0 (en) 1993-03-11 1993-03-11 Recombinant virus
PCT/GB1993/001992 WO1994006920A1 (en) 1992-09-22 1993-09-22 Recombinant viruses displaying a nonviral polypeptide on their external surface

Publications (1)

Publication Number Publication Date
ATE245703T1 true ATE245703T1 (de) 2003-08-15

Family

ID=26301664

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93920989T ATE245703T1 (de) 1992-09-22 1993-09-22 Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren

Country Status (8)

Country Link
US (2) US5723287A (de)
EP (1) EP0670905B1 (de)
JP (1) JPH08504091A (de)
AT (1) ATE245703T1 (de)
AU (1) AU689755B2 (de)
CA (1) CA2145063A1 (de)
DE (1) DE69333115D1 (de)
WO (1) WO1994006920A1 (de)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU689755B2 (en) * 1992-09-22 1998-04-09 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
EP0746625B1 (de) * 1992-11-09 2004-03-31 THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Erzielbare vektorenpartikel
US6534051B1 (en) 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
US5869331A (en) * 1992-11-20 1999-02-09 University Of Medicine & Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
CA2149889A1 (en) * 1992-11-20 1994-06-09 Ralph C. Dornburg Cell-type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
FR2724320B1 (fr) * 1994-09-13 1996-12-20 Transgene Sa Nouvel implant pour le traitement des maladies acquises
US5518042A (en) * 1994-09-16 1996-05-21 Huyck Licensco, Inc. Papermaker's forming fabric with additional cross machine direction locator and fiber supporting yarns
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
GB9506782D0 (en) * 1995-04-01 1995-05-24 British Biotech Pharm Retroviral vectors
GB9514368D0 (en) * 1995-07-13 1995-09-13 Medical Res Council Improvements in or relating to binding assays
GB9516138D0 (en) * 1995-08-05 1995-10-04 Medical Res Council Improvements in or relating to methods of screening substances
AU716466B2 (en) * 1995-09-27 2000-02-24 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
GB9519776D0 (en) 1995-09-28 1995-11-29 Casimir Colin Materials and methods relating to the transfer of nucleic acid into stem cells
US6365344B1 (en) * 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6153380A (en) 1996-01-23 2000-11-28 Rigel Pharmaceuticals, Inc. Methods for screening for transdominant intracellular effector peptides and RNA molecules
WO1997038119A1 (en) * 1996-04-08 1997-10-16 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Reagent and method for targeting retrovirus
EP0973926A1 (de) * 1997-03-14 2000-01-26 Selective Genetics, Inc. Adenovirale vektoren mit verändertem tropismus
EP2008664B1 (de) 1997-04-10 2012-08-29 University Of Southern California Modifizierte Proteine zur Bindung extrazellulärer Matrixkomponenten
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
US6162641A (en) * 1997-06-06 2000-12-19 The Regents Of The University Of Michigan Neuregulin response element and uses therefor
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
AU2002301047B2 (en) * 1997-06-20 2005-11-10 Ciphergen Biosystems, Inc. Retentate Chromatography And Protein Chip Arrays With Applications In Biology And Medicine
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
US6448390B1 (en) 1998-05-20 2002-09-10 The University Of Tennessee Research Corporation Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy
CA2334170A1 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
US7033595B1 (en) 1998-08-04 2006-04-25 Purdue Research Foundation Pseudotyped retroviruses and stable cell lines for their production
WO2000008131A2 (en) * 1998-08-04 2000-02-17 Purdue Research Foundation Pseudotyped retroviruses and stable cell lines for their production
EP1115734A4 (de) * 1998-09-24 2004-07-21 Univ Duke Methoden zur messung von protein-protein wechselwirkungen in lebenden zellen
ATE314095T1 (de) * 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
US6890726B1 (en) 1999-04-06 2005-05-10 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
US7803765B2 (en) * 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
CA2372464C (en) 1999-05-05 2012-07-31 Phylogica Limited Isolating biological modulators from biodiverse gene fragment libraries
US7270969B2 (en) * 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
US7396905B1 (en) 1999-05-21 2008-07-08 Mckeon Frank Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
US7094398B1 (en) 1999-06-01 2006-08-22 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
AU5464000A (en) * 1999-06-01 2000-12-18 University Of Washington Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
US6955808B2 (en) * 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
ATE345819T1 (de) 1999-09-24 2006-12-15 Uab Research Foundation Kapsidmodifiziertes rekombinantes adenovirusund verfahren zu dessen anwendung
CA2386626A1 (en) * 1999-10-15 2001-04-26 Richard Murphy Targeted vectors
EP1240319A1 (de) * 1999-12-15 2002-09-18 Genentech, Inc. "shotgun scanning", eine methode zur kartierung von funktionellen protein epitopen
WO2001062972A1 (en) 2000-02-25 2001-08-30 Biofocus Discovery Limited Methods for identifying candidate polynucleotide molecules encoding a protease
EP1266036A4 (de) 2000-02-25 2003-05-21 Biofocus Discovery Ltd Verfahren und zusammensetzungen zur identifizierung einer protease
DK1268766T3 (da) 2000-03-31 2006-04-10 Cambridge Antibody Tech Forbedringer af ribosom-display
US6762031B2 (en) 2000-06-16 2004-07-13 University Of Medicine And Dentistry Of New Jersey Targeting viral vectors to specific cells
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
CA2429544C (en) * 2000-11-17 2010-10-19 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20030104402A1 (en) * 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
US7176300B2 (en) 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
AU2002255995A1 (en) 2001-03-30 2002-10-15 Avigenics, Inc. Avian lysozyme promoter
US7541512B2 (en) 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US7550650B2 (en) 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7335761B2 (en) 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
EP1461428B1 (de) 2001-12-03 2012-03-21 Alexion Pharmaceuticals, Inc. Verfahren zur Herstellung von Hybridantikörper
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US7132237B2 (en) * 2002-03-13 2006-11-07 Mayo Foundation For Medical Education And Research Avian leukosis viruses and polypeptide display
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7981656B2 (en) * 2002-06-04 2011-07-19 Purdue Research Foundation Pseudotyped retrovirus with modified ebola glycoprotein
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
WO2004089310A2 (en) * 2003-03-31 2004-10-21 The Board Of Regents Of The University Of Texas System High-throughput assay for virus entry and drug screening
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
WO2005056752A2 (en) 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
EP1789453A2 (de) * 2004-05-18 2007-05-30 Genentech, Inc. Haupthüllproteinvarianten des m13-virus zur c-terminalen und bi-terminalen anzeige eines heterologen proteins
CA2568644C (en) * 2004-06-03 2015-11-24 Phylogica Limited Peptide modulators of cellular phenotype and bi-nucleic acid fragment library
WO2006007377A2 (en) 2004-06-16 2006-01-19 The General Hospital Corporation Methods of screening for bridge-1-mediated disorders, including type ii diabetes
EP1769078A1 (de) * 2004-07-01 2007-04-04 VIRxSYS Corporation Vektorverpackungszellinie
CA2573720A1 (en) 2004-07-14 2006-02-23 University Of Utah Research Foundation Netrin-related compositions and uses
CA2574282A1 (en) * 2004-07-21 2006-03-02 Dana-Farber Cancer Institute, Inc. Lentiviral vectors and uses thereof
LT5414B (lt) * 2005-04-13 2007-04-25 Biotechnologijos Institutas Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu
CA2611056C (en) 2005-06-01 2016-06-28 California Institute Of Technology Method of targeted gene delivery using viral vectors
WO2007061141A1 (ja) * 2005-11-24 2007-05-31 Genomidea, Inc. 改変パラミクソウイルスおよびその作製方法
DK1987178T3 (en) 2006-02-20 2015-04-20 Phylogica Ltd Process for the construction and screening of peptide structure libraries
BRPI0714495B8 (pt) 2006-07-21 2021-05-25 California Inst Of Techn lentivírus deficiente para replicação recombinante pseudotipado
US8063012B2 (en) * 2006-09-19 2011-11-22 Phylogica Limited Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor
US20100104572A1 (en) * 2006-11-02 2010-04-29 Sylvie Luria Methods for screening for therapeutic molecules and use of the molecules therefrom
EP2629094A1 (de) 2007-01-24 2013-08-21 Carnegie Mellon University Optische Biosensoren
WO2008122310A1 (en) * 2007-04-04 2008-10-16 Chimera Biotec Gmbh Method for the detection of an analyte in biological matrix
US8822409B2 (en) * 2007-06-20 2014-09-02 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
EP2189539B2 (de) 2008-11-21 2018-06-13 Chimera Biotec GmbH Konjugatkomplexe zum Analytnachweis
JP2012515532A (ja) 2009-01-20 2012-07-12 ラモット アット テル アビブ ユニバーシティ， リミテッド Ｍｉｒ−２１プロモーター駆動性標的がん治療
US9719069B2 (en) 2009-01-27 2017-08-01 University Of Utah Research Foundation Methods and compositions relating to viral latency
ES2900277T3 (es) 2009-03-20 2022-03-16 Mesoblast Inc Producción de células pluripotentes reprogramadas
CN102459576B (zh) 2009-04-27 2015-04-01 渥太华医院研究所 用于调节干细胞的组合物和方法及其应用
AU2010249470B2 (en) * 2009-05-20 2015-06-25 Novimmune S.A. Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
KR101790187B1 (ko) 2009-07-24 2017-10-25 이뮨 디자인 코포레이션 신드비스 바이러스 외피 당단백질로 가성형태화된 렌티바이러스 벡터
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
WO2012092299A1 (en) 2010-12-27 2012-07-05 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
US10208304B2 (en) 2011-04-14 2019-02-19 Regents Of The University Of Minnesota Adenovirus library and methods
AU2012245073B2 (en) 2011-04-21 2016-02-11 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
PH12013502489B1 (en) 2011-06-03 2019-04-24 Xoma Technology Ltd Antibodies specific for tgf-beta
EP3971286A3 (de) 2012-03-26 2022-04-20 The Regents of the University of California Pseudotypisierte lentiviren mit nipah-virus-hülle und verfahren zur verwendung
DK2831095T3 (en) 2012-03-30 2019-02-18 Immune Design Corp LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
WO2014201426A2 (en) 2013-06-14 2014-12-18 University Of Utah Research Foundation Triazol-1-ol analogs anti-retroviral latency drugs
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
US20180042998A1 (en) 2015-03-10 2018-02-15 University Of Massachusetts Targeting gdf6 and bmp signaling for anti-melanoma therapy
CN116327915A (zh) 2015-04-03 2023-06-27 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
WO2017024285A2 (en) 2015-08-06 2017-02-09 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
US11414491B2 (en) * 2016-05-18 2022-08-16 Mayo Foundation For Medical Education And Research Targeting PD-L1 on tumor cells
EP3490600A1 (de) 2016-08-01 2019-06-05 Xoma (Us) Llc Parathormon-rezeptor 1 (pth1r)-antikörper und verwendungen davon
CN110087681A (zh) 2016-09-28 2019-08-02 佐马美国有限公司 结合白细胞介素-2的抗体和其用途
ES3052812T3 (en) 2017-05-08 2026-01-14 Flagship Pioneering Innovations V Inc Compositions for facilitating membrane fusion and uses thereof
WO2020014209A1 (en) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
AU2019378036B2 (en) 2018-11-14 2026-05-07 Flagship Pioneering Innovations V, Inc Compositions and methods for compartment-specific cargo delivery
EP3721896B1 (de) 2019-04-08 2023-11-29 Giuseppe Scalabrino Epidermaler wachstumsfaktor (egf) und varianten davon zur behandlung oder vorbeugung von inflammatorischen demyelinisierenden erkrankungen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012087A1 (en) * 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
WO1992005266A2 (en) * 1990-09-21 1992-04-02 Viagene, Inc. Packaging cells
DE69131908T3 (de) * 1991-02-19 2008-04-03 Oxford Biomedica (Uk) Ltd. Viruspartikel mit veraendertem wirtspektrum
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
AU2512792A (en) * 1991-08-30 1993-04-05 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Defective interfering hiv particles with chimeric cd4-env
WO1993014188A1 (en) * 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
CA2133411A1 (en) * 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
AU689755B2 (en) * 1992-09-22 1998-04-09 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface

Also Published As

Publication number Publication date
US5723287A (en) 1998-03-03
JPH08504091A (ja) 1996-05-07
AU4827893A (en) 1994-04-12
US6297004B1 (en) 2001-10-02
AU689755B2 (en) 1998-04-09
EP0670905B1 (de) 2003-07-23
EP0670905A1 (de) 1995-09-13
DE69333115D1 (de) 2003-08-28
CA2145063A1 (en) 1994-03-31
WO1994006920A1 (en) 1994-03-31

Similar Documents

Publication Publication Date Title
DE69333115D1 (de) Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
Kasahara et al. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions
Lavillette et al. Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments
Morizono et al. Role of phosphatidylserine receptors in enveloped virus infection
Siomi et al. Sequence requirements for nucleolar localization of human T cell leukemia virus type I pX protein, which regulates viral RNA processing
Cheynet et al. Synthesis, assembly, and processing of the Env ERVWE1/syncytin human endogenous retroviral envelope
ATE317909T1 (de) Verabreichung von komplettem faktor viii mit hilfe eines retroviralen systems
Rikkonen et al. Nuclear and nucleolar targeting signals of Semliki Forest virus nonstructural protein nsP2
EP0370458A3 (de) Von synthetischer DNS abgeleitete rekombinante HIV-1-Antigene
AU4427389A (en) Peptides and antibodies that inhibit integrin-ligand binding
CA2285937A1 (en) Modified proteins which bind extracellular matrix components
IL122408A0 (en) Dna encoding a trail polypeptide and its preparation
BR9405507A (pt) Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
CA2133326A1 (en) Fusion proteins comprising tumor necrosis factor receptor
ES8606494A1 (es) Un metodo de producir un peptido o polipeptido sintetico.
ATE263252T1 (de) Erzielbare vektorenpartikel
Zhang et al. Identification of the receptor binding domain of the mouse mammary tumor virus envelope protein
Dreja et al. The effects of N-terminal insertion into VSV-G of an scFv peptide
Battini et al. Definition of a 14-amino-acid peptide essential for the interaction between the murine leukemia virus amphotropic envelope glycoprotein and its receptor
Masood et al. Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors
Bachrach et al. Efficient cell infection by Moloney murine leukemia virus-derived particles requires minimal amounts of envelope glycoprotein
Xu et al. A selective amplifier gene for tamoxifen‐inducible expansion of hematopoietic cells
PT625157E (pt) Epitopes p1a1 e p1a2 da gpiiia da plaqueta sua preparacao e utilizacao
Guibinga et al. Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype
Snitkovsky et al. Targeting avian leukosis virus subgroup A vectors by using a TVA-VEGF bridge protein

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties